JP2023088996A5 - - Google Patents

Info

Publication number
JP2023088996A5
JP2023088996A5 JP2023045826A JP2023045826A JP2023088996A5 JP 2023088996 A5 JP2023088996 A5 JP 2023088996A5 JP 2023045826 A JP2023045826 A JP 2023045826A JP 2023045826 A JP2023045826 A JP 2023045826A JP 2023088996 A5 JP2023088996 A5 JP 2023088996A5
Authority
JP
Japan
Prior art keywords
cancer
day
tsa
aurka
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023045826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023088996A (ja
Filing date
Publication date
Priority claimed from JP2019088425A external-priority patent/JP2019167351A/ja
Application filed filed Critical
Publication of JP2023088996A publication Critical patent/JP2023088996A/ja
Publication of JP2023088996A5 publication Critical patent/JP2023088996A5/ja
Pending legal-status Critical Current

Links

JP2023045826A 2013-08-22 2023-03-22 癌治療 Pending JP2023088996A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US61/869,039 2013-08-22
JP2019088425A JP2019167351A (ja) 2013-08-22 2019-05-08 癌治療
JP2021042699A JP2021105005A (ja) 2013-08-22 2021-03-16 癌治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021042699A Division JP2021105005A (ja) 2013-08-22 2021-03-16 癌治療

Publications (2)

Publication Number Publication Date
JP2023088996A JP2023088996A (ja) 2023-06-27
JP2023088996A5 true JP2023088996A5 (cg-RX-API-DMAC7.html) 2026-04-30

Family

ID=51794948

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016536469A Pending JP2016528297A (ja) 2013-08-22 2014-08-22 癌治療
JP2019088425A Pending JP2019167351A (ja) 2013-08-22 2019-05-08 癌治療
JP2021042699A Pending JP2021105005A (ja) 2013-08-22 2021-03-16 癌治療
JP2023045826A Pending JP2023088996A (ja) 2013-08-22 2023-03-22 癌治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016536469A Pending JP2016528297A (ja) 2013-08-22 2014-08-22 癌治療
JP2019088425A Pending JP2019167351A (ja) 2013-08-22 2019-05-08 癌治療
JP2021042699A Pending JP2021105005A (ja) 2013-08-22 2021-03-16 癌治療

Country Status (12)

Country Link
US (6) US20160199323A1 (cg-RX-API-DMAC7.html)
EP (2) EP3036007B1 (cg-RX-API-DMAC7.html)
JP (4) JP2016528297A (cg-RX-API-DMAC7.html)
KR (5) KR20160033779A (cg-RX-API-DMAC7.html)
CN (2) CN110585184A (cg-RX-API-DMAC7.html)
AU (4) AU2014308700A1 (cg-RX-API-DMAC7.html)
CA (1) CA2921036A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016000397A1 (cg-RX-API-DMAC7.html)
EA (1) EA037667B1 (cg-RX-API-DMAC7.html)
ES (1) ES2755983T3 (cg-RX-API-DMAC7.html)
MX (1) MX381429B (cg-RX-API-DMAC7.html)
WO (1) WO2015027121A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623011B1 (en) * 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
EP1766086A4 (en) 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
GB0519405D0 (en) 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
KR20090014393A (ko) 2006-05-26 2009-02-10 셀진 코포레이션 조합 요법에서 면역조절 화합물을 사용하는 방법 및 조성물
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20110301055A1 (en) 2008-12-05 2011-12-08 Nicholas James Dickens Methods for determining a prognosis in multiple myeloma
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
EP2602330A1 (en) 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EP3623011B1 (en) 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Similar Documents

Publication Publication Date Title
JP2021105005A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP5973684B2 (ja) 癌治療のための使用
HRP20120802T1 (hr) Derivati piperidina i piperazina za lijeäśenje tumora
HK1199710A1 (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
WO2015188169A1 (en) Novel sesquiterpene derivatives and their use in inflammation and cancer treatment
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
CN101600426B (zh) 用于治疗肠道疾病的异山梨醇单硝酸酯衍生物
Xu et al. Berberine inhibits the growth of osteosarcoma through modulating MMP/NM-23 and MAPK/JNK signal pathways
JP2023088996A (ja) 癌治療
CN102475710B (zh) 薯蓣皂苷元及其衍生物在制备肿瘤化疗增敏药物中的应用
Gershanovich et al. Results of clinical study of antitumor action of hydrazine sulfate
JP2013544892A5 (cg-RX-API-DMAC7.html)
PH12021552973A1 (en) Methods of treating urinary system cancers
WO2014153023A1 (en) 5-bromo-indirubins
JP2024541900A5 (cg-RX-API-DMAC7.html)
CN108191860B (zh) 一种HIF-2α小分子抑制剂及其用途
CA2878987C (en) Use of vegfr-3 inhibitors for treating hepatocellular carcinoma
JP2019503370A (ja) ベニバナボロギク抽出物を調製する方法、それにより調製された抽出物、及び抽出物の使用
CN109010333A (zh) 脱氢弯孢霉素在抑制Hedgehog通路中的应用
WO2014157443A1 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
Patwardhan et al. Antioxidant flavonoid baicalein as a dual purpose radiomodifier with promising bench to bedside potential
TWI848990B (zh) 治療化療難治性癌症的新聯合用藥方案
WO2006106984A1 (ja) ピリジン誘導体を有効成分とする放射線治療増強剤
CN107445931A (zh) 土木香内酯衍生物,其药物组合物及其制备方法和用途